EP3485878A1 — Modified-release dosage forms of 5-ht2c agonists useful for weight management
Assigned to Arena Pharmaceuticals Inc · Expires 2019-05-22 · 7y expired
What this patent protects
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine salts and crystalline forms thereof. The present invention further relates to ( R )-8-chloro-1-methyl…
USPTO Abstract
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine salts and crystalline forms thereof. The present invention further relates to ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.
Drugs covered by this patent
- Topamax (topiramate) · Janssen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.